Dapagliflozin in Patients with Chronic Kidney Disease

In this trial, patients with CKD (with or without type 2 diabetes) were randomly assigned to receive dapagliflozin or placebo. The primary composite outcome — a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes — was less f...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 383; no. 15; pp. 1436 - 1446
Main Authors: Heerspink, Hiddo J.L, Stefánsson, Bergur V, Correa-Rotter, Ricardo, Chertow, Glenn M, Greene, Tom, Hou, Fan-Fan, Mann, Johannes F.E, McMurray, John J.V, Lindberg, Magnus, Rossing, Peter, Sjöström, C. David, Toto, Roberto D, Langkilde, Anna-Maria, Wheeler, David C
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 08.10.2020
Subjects:
Aged
Albumin
Antidiabetics
Benzhydryl Compounds - adverse effects
Benzhydryl Compounds - pharmacology
Benzhydryl Compounds - therapeutic use
Cardiovascular Diseases - etiology
Cardiovascular Diseases - mortality
Cardiovascular Diseases - prevention & control
Clinical trials
Congestive heart failure
Creatinine
Death
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetic Nephropathies - drug therapy
End-stage renal disease
Female
Glomerular filtration rate
Glomerular Filtration Rate - drug effects
Glucose
Glucosides - adverse effects
Glucosides - pharmacology
Glucosides - therapeutic use
Humans
Kaplan-Meier Estimate
Kidney diseases
Kidney Failure, Chronic - mortality
Laboratories
Male
Middle Aged
Population
Regression Analysis
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - drug therapy
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
Sodium-Glucose Transporter 2 Inhibitors - pharmacology
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Statistical analysis
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this trial, patients with CKD (with or without type 2 diabetes) were randomly assigned to receive dapagliflozin or placebo. The primary composite outcome — a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes — was less frequent with dapagliflozin.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2024816